Adocia SA (ADOC.PA)
- Previous Close
8.07 - Open
8.21 - Bid --
- Ask --
- Day's Range
8.21 - 8.48 - 52 Week Range
2.77 - 16.16 - Volume
15,481 - Avg. Volume
96,294 - Market Cap (intraday)
121.194M - Beta (5Y Monthly) 0.85
- PE Ratio (TTM)
-- - EPS (TTM)
-2.15 - Earnings Date Apr 24, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.80
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.
www.adocia.comRecent News: ADOC.PA
Performance Overview: ADOC.PA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ADOC.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ADOC.PA
Valuation Measures
Market Cap
115.33M
Enterprise Value
131.80M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
52.83
Price/Book (mrq)
--
Enterprise Value/Revenue
61.30
Enterprise Value/EBITDA
-7.72
Financial Highlights
Profitability and Income Statement
Profit Margin
-189.46%
Return on Assets (ttm)
-30.06%
Return on Equity (ttm)
--
Revenue (ttm)
10.84M
Net Income Avi to Common (ttm)
-20.55M
Diluted EPS (ttm)
-2.15
Balance Sheet and Cash Flow
Total Cash (mrq)
12.13M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.5M
Research Analysis: ADOC.PA
Company Insights: ADOC.PA
ADOC.PA does not have Company Insights